Enovis Corporation reports recurring developments as a medical technology company focused on reconstructive surgery, rehabilitation, pain management, physical therapy and musculoskeletal care. Company news centers on financial results, guidance, organic sales trends and segment performance in Reconstructive and Prevention & Recovery, including updates tied to new product introductions and end-market conditions.
Enovis announcements also include conference participation and investor presentation activity, with business commentary on clinically differentiated solutions intended to enhance patient outcomes, restore motion and support surgeons, clinicians and other healthcare professionals.
Enovis (ENOV) will participate in upcoming investor conferences with its management team. Ben Berry, CFO, will be at the Bank of America Healthcare Conference on May 15th, and CEO Matt Trerotola will be at the William Blair Growth Stock Conference on June 4th. The webcasts and replays will be accessible on the Company's website.
Enovis (NYSE: ENOV) announced strong first-quarter 2024 financial results with a 27% sales growth on a reported basis, net sales of $516 million, and adjusted EBITDA of $83 million. The company reported a net loss of $1.32 per share but adjusted earnings per diluted share of $0.50. Enovis highlighted the acquisition of Lima, new product launches, and an improved 2024 financial outlook.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.